UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For the
month of February,
2017
Commission File Number 001-16174
TEVA PHARMACEUTICAL INDUSTRIES
LIMITED
(Translation
of registrant’s name into English)
5 Basel Street, P.O. Box 3190
Petach Tikva 4951033 Israel
(Address
of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
|
|
Form 20-F ⊠ |
Form 40-F ⃞ |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ⃞
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ⃞
CONTENTS
This Report on Form 6-K consists of the following document, which is attached hereto and incorporated by reference herein:
| 99.1 | Press Release: Teva Reports Full Year and Fourth Quarter 2016 Financial Results |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | ||
|
Date: February 13, 2017 |
By: | /S/ EYAL DESHEH |
| Name: | Eyal Desheh | |
| Title: | Group Executive Vice President, Chief Financial Officer | |